Table 1.

Clinical characteristics of primary and recurrent tumors from 12 patients receiving AI-adjuvant therapy.

Patient	Age	Primary Tumor (before AJ therapy)				Adjuvant HTE	Time to recurrence (Month)	Recurrent Tumor (After AI therapy)
		pTNMA	ERB	PRC	HER2D			Site	ER	PR	HER2
#1	50	pT4cN1M0	+	−	2	LetF	30	Supraclavicular LNI	+	+	0
#2	67	pT2N1M0	+	+	3	AnaG	18	Intra-pectoral LN	+	+	1
#3	72	pT1N0M0	+	−	2	ExeH	43	Subcutaneous nodule	+	−	0
#4	69	pT1N0M0	+	−	3	Ana	58	Subcutaneous nodule	+	+	3
#5	60	pT2N1M0	+	−	1	Ana	27	Subcutaneous nodule	+	−	2
#6	52	pT2N1M0	+	+	0	Ana	33	Subclavicular LN	+	+	0
#7	59	pT4bN1M0	+	+	1	Ana	53	Supraclavicular LN	−	−	1
#8	78	pT1N1M0	+	+	1	Ana	72	Supraclavicular LN	+	+	2
#9	53	pT2N0M0	+	+	0	Exe	72	Subclavicular LN	+	+	0
#10	53	pT2N1M0	+	+	1	Exe	68	Subcutaneous nodule	+	+	1
#11	78	pT3N1M0	+	−	0	Exe	24	Subcutaneous nodule	+	−	0
#12	53	pT2N2M0	+	+	0	Ana	41	Ipslateral breast	+	+/−	1

^ApTNM: pathological tumor-lymph nodes-metastasis classification according to the Union Internationale Contra le Cancer (UICC).

^BER: Estrogen receptor status.

^CPR: Progesterone receptor status.

^DHER2/neu status: HER2.

^EHT: Hormone therapy.

^FLet: Letrozole.

^GAna: Anastrozole.

^HExe: Exemestane.

^ILN: Lymph nodes.